Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo-Reference-Cited by-同舟云学术

Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo

Published:2008-07 Issue:1 Volume:79 Page:49-61
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Schleiss Mark,Eickhoff Jan,Auerochs Sabrina,Leis Martina,Abele Silke,Rechter Sabine,Choi Yeon,Anderson Jodi,Scott Gillian,Rawlinson William,Michel Detlef,Ensminger Stephan,Klebl Bert,Stamminger Thomas,Marschall Manfred

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference43 articles.

1. Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase;Baek;Virology,2004

2. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors;Bergman;Int. J. Pharm.,2007

3. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine (BW B759U) induces reduced levels of BW B759U triphosphate;Biron;Proc. Natl. Acad. Sci. U.S.A.,1986

4. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action;Biron;Antimicrob. Agents Chemother.,2002

5. Cellular targets of gefitinib;Brehmer;Cancer Res.,2005

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-(2-Carboxyphenyl)oxalamides in the synthesis of the quinazoline central nervous system depressant methaqualone and fused biheterocyclic systems;Russian Chemical Bulletin;2024-07

2. N-Heterocycles as Promising Antiviral Agents: A Comprehensive Overview;Molecules;2024-05-10

3. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies;European Journal of Medicinal Chemistry;2023-11

4. Preparing for the next viral threat with broad-spectrum antivirals;Journal of Clinical Investigation;2023-06-01

5. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2;MedComm;2023-05-14